Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
02/2010
02/16/2010US7662853 Monoacetyldiacylglycerol derivative for the treatment of sepsis
02/16/2010US7662849 N-cyanomethyl-2R-[(benzenesulfonyliminomethyl)amino]-3-(2-difluoromethoxyphenylmethanesulfonyl)-propionamide; treating autoimmune disorders
02/16/2010US7662845 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
02/16/2010US7662843 Isoxazoline compounds having MIF antagonist activity
02/16/2010US7662835 Methods of treating allergic reactions using an anhydrous form of antihistaminic piperidine derivatives
02/16/2010US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma
02/16/2010US7662817 Psychological disorders; central nervous system disorders; antidepressants; anxiolytic agents; stress reliever; irritable bowel syndrome
02/16/2010US7662814 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases
02/16/2010US7662796 Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
02/16/2010US7662782 Melanocortin 1 receptor selective compounds
02/16/2010US7662778 a compound containing cyclic tetrapeptide coupled to amide, ester, ketone groups; apoptosis and cell differentiation inducer; cancer metastasis and angiogenesis inhibitor; catalytic hydrogenation, acid treatment, fluoride anion treatment, or hydrolysis for deblocking; coupling cyclic tertrapeptide
02/16/2010US7662633 Method of screening for inhibitors of osteopontin
02/16/2010US7662395 Recombinant virus encoding an antigen of a disease state; second recombinant virus encoding an immunostimulatory molecule with an exogenous immunostimulatory molecule, chemotherapeutic drug, antibiotic, antiviral drug or antifungal drug.
02/16/2010US7662371 Composition for lowering the concentration of intestinal pathogenic peptides
02/16/2010CA2450922C Piperidines for use as orexin receptor antagonists
02/16/2010CA2402436C Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
02/16/2010CA2220433C Il-6 activity inhibitor
02/16/2010CA2177612C Nucleic acids encoding a house dust mite allergen, der p iii, and uses therefor
02/11/2010WO2010017403A2 Therapeutic compositions, devices and methods for observing treated tissues
02/11/2010WO2010017350A1 Aminopyridine kinase inhibitors
02/11/2010WO2010017154A2 Modulation of toll-like receptor 3 expression by antisense oligonucleotides
02/11/2010WO2010017131A2 Modulation of toll-like receptor 7 expression by antisense oligonucleotides
02/11/2010WO2010017103A2 Fully human anti-human nkg2d monoclonal antibodies
02/11/2010WO2010017086A1 Effectors of par-2 activation and their use in the modulation of inflammation
02/11/2010WO2010016525A1 Immunity inducer
02/11/2010WO2010015148A1 Oligodeoxynucleotides with function of immunosuppression
02/11/2010WO2010015098A1 Veterinary pharmaceutical formulation comprising an rna recombinant particle encoding a cu/zn superoxide dismutase protein of ruminant pathogenic bacteria and at least one rna alphavirus belonging to the semliki forest virus family
02/11/2010WO2009157858A8 Use of cyclolignans for the treatment of a hyperactive immune system
02/11/2010WO2009116088A4 Stem cell composition for inducing transplant tolerance
02/11/2010US20100035967 Modulation of toll-like receptor 9 expression by antisense oligonucleotides
02/11/2010US20100035959 Novel sphingosine kinase type 1 inhibitors, compositions and processes for using same
02/11/2010US20100035943 Oxa-and thiadiazoles and their use as metalloproteinase inhibitors
02/11/2010US20100035926 Pyrazole derivatives as non-steroidal glucocorticoid receptor ligands
02/11/2010US20100035903 administering 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile or salts, for the treatment of dermatitis, Crohn's disease, inflammatory bowel disease, transplant rejection, lupus, multiple sclerosis, arthritis, psoriasis, diabetes and autoimmune diseases
02/11/2010US20100035891 Pharmaceutically Active Compounds
02/11/2010US20100035875 Triazolopyridine jak inhibitor compounds and methods
02/11/2010US20100035847 Genes for biosynthesis of tetracycline compounds and uses thereof
02/11/2010US20100035842 Amino alcohol compounds or phosphonic acid derivatives thereof
02/11/2010US20100035841 Inhibitors of tyrosine kinases and uses thereof
02/11/2010US20100035828 Milk oligosaccharide for stimulating the immune system
02/11/2010US20100035818 Optimized expression of hpv 52 l1 in yeast
02/11/2010US20100035806 Compositions and Methods for Detection and Modulation of T Cell Mediated Immune Responses Against Viral Vectors Utilized for Gene Therapy
02/11/2010US20100034847 Multiple vaccination including Serogroup C Meningococcus
02/11/2010US20100034824 Targeted biocides
02/11/2010US20100034823 Crystalline anti-hTNFalpha antibodies
02/11/2010US20100034817 Compositions and methods for the treatment of immune related diseases
02/11/2010US20100034812 Antibodies Specific for BET V1 and Use Thereof in the Prevention and Treatment of BET V1- Induced Diseases
02/11/2010US20100034782 Methods of Using Anti-Thymocyte Globulin and Related Agents
02/11/2010US20100034774 Serotype of adenovirus and uses thereof
02/11/2010US20100034771 Combination Of Cytokine And Cytokine Receptor For Altering Immune System Functioning
02/11/2010CA2735710A1 Sting (stimulator of interferon genes), a regulator of innate immune responses
02/11/2010CA2733041A1 Effectors of par-2 activation and their use in the modulation of inflammation
02/11/2010CA2732765A1 Aminopyridine kinase inhibitors
02/11/2010CA2732283A1 Immunity-inducing agent
02/10/2010EP2151438A1 Pharmaceutical containing ppar agonist
02/10/2010EP2151436A1 Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
02/10/2010EP2150618A1 Il-12 immunotherapy for cancer
02/10/2010EP2150564A2 Antagonists to il-17a, il-17f, and il-23p19 and methods of use
02/10/2010EP1525191B1 Novel method for preparing styryl pyrazole, isoxazole and isothiazole derivatives
02/10/2010EP1490365B1 Azaindoles as inhibitors of c-jun n-terminal kinases
02/10/2010EP0910655B1 Vaccines for treatment of lymphoma and leukemia
02/10/2010CN101643789A RNA interference mediating small RNA molecules
02/10/2010CN100588647C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
02/09/2010US7659407 Pharmaceutical compounds
02/09/2010US7659385 Polynucleotides encoding molecules designated LDCAM
02/09/2010US7659375 Interleukin specific immunoglobulin for prevention and treatment of vision, autoimmune, inflammatory and diabetic disorders
02/09/2010US7659370 Nervous system protein for use in treatment and prevention of nervous system and seizure disorders
02/09/2010US7659272 N-[phenyl or heteroaryl carbonoyl pyridyl] arylsulfonamides; antiinflammatory, antianaphylactic agents; transplant rejection, gastointestinal, respriatory system and skin disorders
02/09/2010US7659267 2-(3-cyanophenyl)-4H-1,3-benzothiazin-4-one; cardiovascular, bone or joint diseases, infectious, inflammatory, kidney diseases; safe and good effects of cell death inhibition, Migration Inhibitory Factor (MIF) binding
02/09/2010US7659249 Membrane-permeable NFAT inhibitory peptide
02/09/2010US7659117 Immunostimulatory fusion proteins comprising polypeptide antigen for generating protective DC-induced T-cell-mediated immune responses; metastatic cancers
02/09/2010US7659103 Nucleic acid construct containing fulllength genome of human hepatitis C virus, recombinant fulllength virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus Particle
02/09/2010US7658929 Derived from pathogenic microorganisms, useful for vaccination and diagnosis; tuberculosis; detection of CD4+ T lymphocytes recognizing at least one glycopeptide obtained from pathogenic microorganism
02/09/2010US7658928 Using microbiocidal peptides to enhance uptake of cytokines, polylysines, polyarginine and/or aluminum hydroxide in antigen presenting cells; stimulating host protection from invading pathogens
02/09/2010CA2484954C 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
02/09/2010CA2451562C Piperazine compound
02/09/2010CA2451240C Cyclic diamine compound with 6 membered ring groups
02/09/2010CA2440760C Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
02/09/2010CA2439593C Heterocyclic compounds for aging-related and diabetic vascular complications
02/09/2010CA2418224C Pharmaceutical composition
02/09/2010CA2192092C Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
02/04/2010WO2010014930A2 Therapeutic agents
02/04/2010WO2010014836A2 Tgr5 modulators and methods of use thereof
02/04/2010WO2010013846A1 New therapeutic agent for malignant mesothelioma and immunostimulant
02/04/2010WO2010013805A1 Aminopropylidene derivative
02/04/2010WO2010013350A1 S/o type transdermal immunizing agent
02/04/2010WO2010013143A2 Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
02/04/2010WO2010012745A2 Benzimidazoles
02/04/2010WO2010012069A1 Multivalent vaccines based on papaya mosaic virus and uses thereof
02/04/2010WO2010012037A1 6-substituted isoflavonoid compounds and uses thereof
02/04/2010WO2009151496A9 Induction of proliferation, effector molecule expression, and cytolytic capacity of hiv-specific cd8+ t cells
02/04/2010WO2009150371A3 Nanoparticles containing a peptide, vectors containing the same and pharmaceutical uses of said nanoparticles and said vectors
02/04/2010US20100029767 Anthranilic acid derivatives
02/04/2010US20100029753 Modulators of ccr9 receptor and methods of use thereof
02/04/2010US20100029719 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors
02/04/2010US20100029709 Novel compounds useful for the treatment of degenerative and inflammatory diseases
02/04/2010US20100029705 Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis
02/04/2010US20100029699 Matrix metalloproteinase inhibitors
02/04/2010US20100029695 Method of treating dermatitis comprising administering a chymase inhibitor
02/04/2010US20100029692 Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders
1 ... 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 ... 1172